Jump Financial LLC Acquires New Shares in Roivant Sciences Ltd. (NASDAQ:ROIV)

Jump Financial LLC bought a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 11,417 shares of the company’s stock, valued at approximately $135,000.

A number of other hedge funds also recently added to or reduced their stakes in ROIV. Barclays PLC lifted its stake in Roivant Sciences by 19.7% in the third quarter. Barclays PLC now owns 459,521 shares of the company’s stock valued at $5,302,000 after buying an additional 75,609 shares during the last quarter. Virtu Financial LLC bought a new stake in Roivant Sciences in the third quarter valued at $207,000. Te Ahumairangi Investment Management Ltd lifted its stake in Roivant Sciences by 19.9% in the third quarter. Te Ahumairangi Investment Management Ltd now owns 201,612 shares of the company’s stock valued at $2,313,000 after buying an additional 33,467 shares during the last quarter. Tyro Capital Management LLC lifted its stake in Roivant Sciences by 0.6% in the third quarter. Tyro Capital Management LLC now owns 1,754,976 shares of the company’s stock valued at $20,252,000 after buying an additional 10,649 shares during the last quarter. Finally, Retirement Systems of Alabama lifted its stake in Roivant Sciences by 26.9% in the third quarter. Retirement Systems of Alabama now owns 530,022 shares of the company’s stock valued at $6,116,000 after buying an additional 112,286 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ROIV shares. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Monday, April 21st. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th.

Roivant Sciences Stock Performance

Shares of ROIV opened at $11.19 on Tuesday. The firm has a market capitalization of $7.98 billion, a price-to-earnings ratio of -74.60 and a beta of 1.25. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $13.06. The stock’s fifty day moving average is $10.35 and its 200-day moving average is $11.14.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Analysts forecast that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Eric Venker sold 315,522 shares of Roivant Sciences stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $11.06, for a total transaction of $3,489,673.32. Following the transaction, the chief operating officer now directly owns 959,457 shares of the company’s stock, valued at $10,611,594.42. The trade was a 24.75 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Rakhi Kumar sold 227,500 shares of Roivant Sciences stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $10.43, for a total value of $2,372,825.00. Following the transaction, the chief accounting officer now directly owns 163,264 shares in the company, valued at approximately $1,702,843.52. The trade was a 58.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,395,541 shares of company stock valued at $14,922,538 over the last three months. Company insiders own 7.90% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.